Terray Therapeutics is the latest firm to score a significant heap of cash in order to develop an artificial intelligence (AI)-based drug discovery and development platform, and it is armed with what it calls the world’s largest chemistry dataset, along with partnerships with Bristol Myers Squibb Company and Calico Life Sciences.
Terray Aims To Further Develop AI Platform, Move Into Clinic In 2026
The AI-focused biotech closed a $120m series B funding round, bringing the total funding it has raised to $200m, as it aims to have a product candidate in the clinic in 2026.
